Render Target: STATIC
Render Timestamp: 2024-11-21T13:24:40.752Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:58:35.531
Product last modified at: 2024-09-30T08:02:17.356Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

BACE2 (E3Y9Q) Rabbit mAb #80357

Filter:
  • WB
  • IF

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 57
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunofluorescence (Frozen) 1:400 - 1:1600
    Immunofluorescence (Immunocytochemistry) 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    BACE2 (E3Y9Q) Rabbit mAb recognizes endogenous levels of total BACE2 protein. This antibody does not cross-react with BACE1 protein. Weak, non-specific labeling of the smooth muscle may be observed by immunofluorescence. Species cross-reactivity for immunofluorescence is mouse only.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human BACE2 protein.

    Background

    β-secretase 2 (BACE2) is a type I transmembrane aspartic acid protease that catalyzes the processing of its substrates, including amyloid precursor protein (APP). Pro-BACE2 is synthesized in the endoplasmic reticulum (ER) before it is transported to the trans-Golgi network where it is cleaved by furin to become its mature form. BACE2 then migrates to the plasma membrane where it acts upon its substrates (1,2). Mature BACE2 functions as a θ-secretase, cleaving APP to produce a carboxyl-terminal fragment of 80 amino acids (C80) (3,4). Similar to its homolog BACE, BACE2 can also cleave APP at the β-site, releasing a soluble, extracellular APP-β (sAPP-β) ectodomain and generating a membrane-bound, carboxy-terminal fragment consisting of 99 amino acids (C99). Mutations within the juxtamembrane helix (JH) of APP, or the binding of this region by the neuronal chaperone protein clusterin, enables this BACE2-mediated β-cleavage. Additional processing of C99 by γ-secretase generates the amyloid β-peptide (Aβ) that forms aggregates in the brains of Alzheimer's disease (AD) patients (5).

    BACE2 expression in the brain is lower, both in comparison to that of BACE and to its expression level in the periphery. However, expression of BACE2 within the brain has been seen to increase during aging and in the context of neurodegenerative disease, further supporting the role it may play in disease progression (5,6). BACE2 may also play a role in disease progression in the periphery. For instance, in the pancreas, BACE2 has been implicated in regulating β-cell function and mass in the context of type II diabetes (2,7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.